Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL27542577 | 0.96 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL19514150 | 0.94 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL531185 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL9937710 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL4287074 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL10804023 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL4629448 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL21250225 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL20703797 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL3039720 | 0.94 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145447-B2 | Photoconvertible fluorescent proteins | ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | claimed |
| US-9145447-B2 | Photoconvertible fluorescent proteins | ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20110214192-A1 | PHOTOCONVERTIBLE FLUORESCENT PROTEINS | UNIVERSITY OF ALBERTA, TEC EDMONTON (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7935801-B2 | non-oligomerizing Clavularia teal fluorescent protein (TFP) variant having a tyrosine-derived chromophore; nucleic acid compatible with mammalian codon usage | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-05-03 | — | — | US | disclosed |
| US-7790868-B2 | Teal fluorescent proteins (mTFP1) | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090170194-A1 | TEAL FLUORESCENT PROTEINS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20060275827-A1 | TEAL FLUORESCENT PROTEINS (mTFP1) | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2006-12-07 | — | — | US | disclosed |
| US-6372727-B1 | ADMINISTERING IRON PORPHYRIN TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; TREATING OXIDATIVE INJURY RELATED TO PEROXYNITRITE | UAB RESEARCH FOUNDATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001026655-A1 | METALLOPORPHYRIN TREATMENT OF NEUROLOGIC DISEASE | UAB RESEARCH FOUNDATION (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110214192-A1 | PHOTOCONVERTIBLE FLUORESCENT PROTEINS | DCLRE1B, PABPC4, RNGTT | ADORA3 2392/4885SLC7A5 3687/4885PTGS1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.